Cancer discovery最新文献

{"title":"An Autochthonous Model of Lung Cancer Identifies Requirements for Cellular Transformation in the Naked Mole-Rat.","authors":"Alyssa Shepard,Daniel K Lester,Scott Troutman,Sany Hoxha,Walid T Khaled,Ewan St J Smith,Thomas J Park,Rochelle Buffenstein,Dongliang Du,Mingxiang Teng,Christine M Dengler-Crish,Kenneth Y Tsai,Elsa R Flores,Andrea Ventura,Joseph L Kissil","doi":"10.1158/2159-8290.cd-25-0526","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-0526","url":null,"abstract":"There is growing interest in understanding the mechanisms underlying differences in cancer incidence among species (comparative oncology). The naked mole-rat (NMR) is often referenced as \"cancer-resistant\" and prior studies focused on identifying mechanisms explaining this. However, efforts to assess this in vivo have been limited. Herein, we provide evidence that the NMR presents as a novel autochthonous model of lung tumor initiation, driven by an introduction of the oncogenic Eml4-Alk fusion protein using CRISPR-mediated genome editing. Whereas in mice the inversion alone is sufficient to drive tumorigenesis, the inversion alone was insufficient to drive tumorigenesis in the NMR lung and tumor development required additional losses of the tumor suppressors p53 and pRb. Our findings suggest that the proposed \"resistance\" of the NMR to the development of cancer may reflect that the genetic events leading to tumor initiation are likely to be comparable to those present in human cells.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"51 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145008789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Dark Side of NK Cells in Cancer Immunotherapy.","authors":"Felipe Galvez-Cancino,Maria Armero,David R Withers,Paula Molero-Glez,Ana Melero,Belen Palencia,Ignacio Melero","doi":"10.1158/2159-8290.cd-25-1042","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-1042","url":null,"abstract":"NK cells are a subset of innate lymphoid cells originally identified in mice and humans based on their ability to mediate cytotoxicity against transformed cells. However, two recent back-to-back studies in this issue of Cancer Discovery reveal that NK cell infiltration is not always beneficial; rather, it can impair the efficacy of immune checkpoint blockade through immune-regulatory mechanisms. See related article by Pozniak et al., p. 1819 See related article by Song et al., p. 1835.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"1206 1","pages":"1777-1779"},"PeriodicalIF":28.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aryl hydrocarbon receptor ligands drive pancreatic cancer initiation and progression through pro-tumorigenic T cell polarization.","authors":"Brian D Griffith,Padma Kadiyala,Jake McGue,Lei Sun,Aadith Kumar,Carlos E Espinoza,Katelyn L Donahue,Matthew K Iyer,Cameron Speyer,Sarah Nelson,Andrew Spiteri,Ahmed M Elhossiny,Kristee Brown,Holly Attebury,Filip Bednar,Eileen S Carpenter,Ilona Kryczek,Yaqing Zhang,Weiping Zou,Marina Pasca di Magliano,Timothy L Frankel","doi":"10.1158/2159-8290.cd-25-0377","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-0377","url":null,"abstract":"Although smoking is a risk factor for pancreatic adenocarcinoma (PDAC), the underlying mechanism promoting tumorigenesis and progression are unknown. Here, we show that aryl hydrocarbon receptor ligands found in cigarette smoke, like the carcinogen 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), promote pancreatic dysplasia and PDAC progression in a mouse model of this disease. This effect is mediated by AhR activation in CD4+ T cells, leading to their polarization to interleukin-22 (IL22) producing TH22 cells and to regulatory T cells (Treg) accumulation, ultimately driving a blunted CD8+ T cell effector response. Analysis of human pancreata from organ donors revealed that smokers have increased AhR activation relative to non-smokers. Similarly, PDAC tumors from patients with a history of cigarette smoking presented with increased Treg accumulation compared to non-smokers. These findings support a model whereby AhRLs in cigarette smoke promote tumorigenesis and progression of PDAC through dysregulation of immune responses.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"112 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144962653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detecting Cancer Early with Ultrasensitive Multimodal Liquid Biopsy.","authors":"Giovanni Crisafulli,Nadia Saoudi Gonzalez,Giorgio Patelli,Alberto Bardelli","doi":"10.1158/2159-8290.cd-25-1025","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-1025","url":null,"abstract":"Wang and colleagues showed that ctDNA can be detected in plasma up to 3 years prior to clinical diagnosis. The study highlights the need for ultrasensitive and multimodal approaches that integrate the detection of mutations and copy-number changes with advanced computational platforms to deliver effective early-detection strategies. See related article by Wang et al., p. 1794.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"2018 1","pages":"1774-1776"},"PeriodicalIF":28.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960094","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Privilege Within: Regulatory T Cells Tip the Balance in Favor of Lymph Node Metastasis.","authors":"Lutz Menzel,Timothy P Padera","doi":"10.1158/2159-8290.cd-25-1043","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-1043","url":null,"abstract":"Kahn and colleagues reveal that lymph nodes (LN) provide an intrinsically immunosuppressive niche that prevents effector function of activated CD8+ T cells in LNs and allows immunogenic tumor cells to survive and drive cancer progression, independent of tumor-derived preconditioning. By locally suppressing IL2 availability, regulatory T cells in LNs impair CD8+ T-cell cytotoxicity-a mechanism with important implications for immune checkpoint therapy and LN-targeted immunomodulation. See related article by Kahn et al., p. 1949.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"14 1","pages":"1780-1782"},"PeriodicalIF":28.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960093","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Histologic Transformation in Cancer: The Path for Clinical Translation.","authors":"Ioannis Vathiotis,Avisek Banerjee,Utsav Sen,Felix C Saalfeld,Debdatta Halder,Andriani Charpidou,Konstantinos N Syrigos,Hidehito Horinouchi,Ashutosh K Tewari,Mark A Dawson,Martin Wermke,Triparna Sen","doi":"10.1158/2159-8290.cd-24-1866","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-24-1866","url":null,"abstract":"Lineage plasticity, a critical hallmark of cancer progression, enables tumor cells to evade inhibition of primary oncogenic pathways through histologic transformation. This adaptive process, driven by stemness-associated features and epigenetic reprogramming, poses significant challenges in treatment. Using non-small cell lung cancer and prostate cancer as models, we examine the utility of tissue and liquid biopsies in detecting histologic transformations and tailoring treatments to specific subtypes, which has profound clinical implications, potentially improving outcomes in patients with advanced, therapy-resistant disease. We also discuss emerging therapeutic strategies, including novel molecular targets, and address ongoing clinical challenges in managing treatment-emergent histologic transformation.SIGNIFICANCEThe advent of highly effective molecularly targeted therapies results in increased recognition of treatment-emergent histologic transformation. This review not only summarizes current evidence on diagnosis and management of lineage plasticity but also explores therapeutic strategies under study, outlining a framework for clinical translation and successful drug development.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"29 1","pages":"1783-1793"},"PeriodicalIF":28.2,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144960100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vascular Normalization Augments the Antitumor Efficacy of Combined HDAC Inhibitor with Immunotherapy in Solid Tumors.","authors":"Min Wang, Yanxing Chen, Lin Tian, Chenyi Wu, Jiaying Chen, Jiajia Hu, Runjie Huang, Yingnan Wang, Jinling Zhang, Xiao-Jie Ouyang, Liqin Wang, Ying Jin, Qi Zhao, Feng Wang, Rui-Hua Xu","doi":"10.1158/2159-8290.CD-24-1033","DOIUrl":"10.1158/2159-8290.CD-24-1033","url":null,"abstract":"<p><p>Immunotherapy has made remarkable strides in the treatment of solid tumors, but its efficacy as a single agent in immunologically cold tumors remains limited. Therefore, it is necessary to explore novel drug combinations to further optimize immunotherapy. Herein, we demonstrated that the histone deacetylase inhibitor (HDACi) chidamide enhanced chromatin accessibility at the promoters of genes that encode effector molecules in CD8+ T cells, thereby augmenting their antitumor capabilities. However, HDACi also induced the expression of VEGFA in protumorigenic macrophages, which led to vascular abnormalization and hindered immune cell infiltration, compromising its potential synergistic effect with immunotherapy. Accordingly, combining antiangiogenic therapy counteracted the angiogenic effects of HDACi, collaboratively unleashing the infiltration and functionality of cytotoxic CD8+ T cells. These findings were confirmed by single-cell RNA sequencing data from our patient samples. Thus, through mechanistic research, we propose a new therapeutic approach by the combination of HDACi, antiangiogenic therapy, and immunotherapy, highlighting its potential application across diverse solid tumors.</p><p><strong>Significance: </strong>The challenges of tumor therapy primarily lie in developing novel intervention strategies to shift the tumor microenvironment toward an antitumor phenotype. Herein, we discovered that the combination of HDACi and antiangiogenic therapy promoted the functionality and infiltration of CD8+ T cells, ultimately remodeling the tumor microenvironment and boosting immunotherapy efficacy.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"1883-1904"},"PeriodicalIF":33.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Federated Deep Learning Enables Cancer Subtyping by Proteomics.","authors":"Zhaoxiang Cai, Emma L Boys, Zainab Noor, Adel T Aref, Dylan Xavier, Natasha Lucas, Steven G Williams, Jennifer M S Koh, Rebecca C Poulos, Yangxiu Wu, Michael Dausmann, Karen L MacKenzie, Adriana Aguilar-Mahecha, Carolina Armengol, Maria M Barranco, Mark Basik, Elise D Bowman, Roderick Clifton-Bligh, Elizabeth A Connolly, Wendy A Cooper, Bhavik Dalal, Anna DeFazio, Martin Filipits, Peter J Flynn, J Dinny Graham, Jacob George, Anthony J Gill, Michael Gnant, Rosemary Habib, Curtis C Harris, Kate Harvey, Lisa G Horvath, Christopher Jackson, Maija R J Kohonen-Corish, Elgene Lim, Jia Jenny Liu, Georgina V Long, Reginald V Lord, Graham J Mann, Geoffrey W McCaughan, Lucy Morgan, Leigh Murphy, Sumanth Nagabushan, Adnan Nagrial, Jordi Navinés, Benedict J Panizza, Jaswinder S Samra, Richard A Scolyer, John Souglakos, Alexander Swarbrick, David Thomas, Rosemary L Balleine, Peter G Hains, Phillip J Robinson, Qing Zhong, Roger R Reddel","doi":"10.1158/2159-8290.CD-24-1488","DOIUrl":"10.1158/2159-8290.CD-24-1488","url":null,"abstract":"<p><p>Artificial intelligence applications in biomedicine face major challenges from data privacy requirements. To address this issue for clinically annotated tissue proteomic data, we developed a federated deep learning approach (ProCanFDL), training local models on simulated sites containing data from a pan-cancer cohort (n = 1,260) and 29 cohorts held behind private firewalls (n = 6,265), representing 19,930 replicate data-independent acquisition mass spectrometry runs. Local parameter updates were aggregated to build the global model, achieving a 43% performance gain on the hold-out test set (n = 625) in 14 cancer subtyping tasks compared with local models and matching centralized model performance. The approach's generalizability was demonstrated by retraining the global model with data from two external, data-independent acquisition mass spectrometry cohorts (n = 55) and eight acquired by tandem mass tag proteomics (n = 832). ProCanFDL presents a solution for internationally collaborative machine learning initiatives using proteomic data, for example, for discovering predictive biomarkers or treatment targets while maintaining data privacy.</p><p><strong>Significance: </strong>A federated deep learning approach applied to human proteomic data, acquired using two distinct proteomic technologies from 40 tumor cohorts across eight countries, enabled accurate cancer histopathologic subtyping while preserving data privacy. This approach will enable the privacy-compliant development of large-scale proteomic artificial intelligence models, including foundation models, across institutions globally.</p>","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":" ","pages":"1803-1818"},"PeriodicalIF":33.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12409279/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Defining the antitumor mechanism of action of a clinical-stage compound as a selective degrader of the nuclear pore complex","authors":"Linjie Yuan, Wenzhi Ji, Brendan G. Dwyer, Joey Lu, Jing Bian, Gianna M. Colombo, Michael J. Martinez, Daniel Fernandez, Nick A. Phillips, Michelle T. Tang, Christine Wenjie. Zhou, Nirk E. Quispe Calla, Cesar Guzman Huancas, Michael Eckart, Jessica Tran, Hannah M. Jones, Tian Qiu, John G. Doench, Matthew G. Rees, Jennifer A. Roth, Michael D. Cameron, Gregory W. Charville, Calvin J. Kuo, Scott J. Dixon, Tinghu Zhang, Stephen M. Hinshaw, Nathanael S. Gray, Steven M. Corsello","doi":"10.1158/2159-8290.cd-25-0271","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-25-0271","url":null,"abstract":"Cancer cells are acutely dependent on nuclear transport due to elevated transcriptional activity, suggesting an unrealized opportunity for selective therapeutic inhibition of the nuclear pore complex. Through large-scale phenotypic profiling of cancer cell lines, genome-scale functional genomic modifier screens, and mass spectrometry-based proteomics, we discovered that the clinical drug PRLX-93936 is a molecular glue that binds and reprograms the TRIM21 ubiquitin ligase to degrade the nuclear pore complex. Upon compound-induced TRIM21 recruitment, the nuclear pore is ubiquitylated and degraded, resulting in the loss of short-lived cytoplasmic mRNA transcripts and induction of cancer cell apoptosis. Direct compound binding to TRIM21 was confirmed via surface plasmon resonance and x-ray crystallography, while compound-induced TRIM21-nucleoporin complex formation was demonstrated through multiple orthogonal approaches in cells and in vitro. Phenotype-guided optimization yielded compounds with 10-fold greater potency and drug-like properties with robust pharmacokinetics and efficacy against pancreatic cancer xenografts and patient-derived organoids.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"66 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2025-09-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144930323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Detection of human brain cancers using genomic and immune cell characterization of cerebrospinal fluid through CSF-BAM","authors":"Alexander H. Pearlman, Yuxuan Wang, Anita Kalluri, Megan Parker, Joshua D. Cohen, Jonathan Dudley, Jordina Rincon-Torroella, Yuanxuan Xia, Ryan Gensler, Melanie Alfonzo Horowitz, John N. Theodore, Lisa Dobbyn, Maria Popoli, Janine Ptak, Natalie Silliman, Kathy Judge, Peter A. Calabresi, Mari Groves, Christopher M. Jackson, Eric M. Jackson, George I Jallo, Michael Lim, Mark Luciano, Debraj Mukherjee, Jarushka Naidoo, Sima Rozati, Cole H. Sterling, Jon Weingart, Carl Koschmann, Alireza Mansouri, Michael Glantz, David Kamson, Karisa C. Schreck, Carlos A. Pardo, Matthias Holdhoff, Maximilian F. Konig, Suman Paul, Kenneth W. Kinzler, Nickolas Papadopoulos, Bert Vogelstein, Christopher Douville, Chetan Bettegowda","doi":"10.1158/2159-8290.cd-24-1788","DOIUrl":"https://doi.org/10.1158/2159-8290.cd-24-1788","url":null,"abstract":"Patients with radiographically detectable lesions in their brain or other symptoms compatible with brain tumors pose challenges for diagnosis. The only definitive way to diagnose such patients is through brain biopsy, an invasive and dangerous procedure. Here we present a new workflow termed “CSF-BAM” that simultaneously identifies B cell or T cell receptor sequences, Aneuploidy, and Mutations using amplification of both strands of the DNA from cerebrospinal fluid (CSF) samples. We applied CSF-BAM to a validation set of 209 samples from patients with brain cancers. Among the 129 samples from patients with the most common aggressive cancer types, the sensitivity of detection was 81%. None of 30 CSF-BAM assays were positive in CSF samples from patients without brain cancers (100% specificity). CSF-BAM provides an integrated approach to identify neoplasia in the central nervous system, provides information about the genetics and immune environment, and has the potential to inform patient management.","PeriodicalId":9430,"journal":{"name":"Cancer discovery","volume":"49 1","pages":""},"PeriodicalIF":28.2,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144899112","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}